March 26, 2018 / 5:14 AM / a year ago

Roche's Tecentriq cocktail helps lung cancer patients live longer

ZURICH, March 26 (Reuters) - Swiss drugmaker Roche’s immunotherapy Tecentriq combined with other medicines helped people with advanced lung cancer live longer, compared to patients receiving an older drug combination, the company said in a statement on Monday.

Treatment mixing Tecentriq with Avastin and chemotherapies carboplatin and paclitaxel boosted overall survival in first-line treatment, compared to patients who received Avastin plus carboplatin and paclitaxel. Roche said it would submit the data to authorities and hopes for a quick approval. (Reporting by John Miller; editing by Brenna Hughes Neghaiwi)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below